FDA to ‘rapidly work’ towards emergency use authorization for Pfizer-BioNTech vaccine

The Foods and Drug Administration claimed these days that adhering to yesterday’s favourable advisory committee conference consequence about the Pfizer-BioNTech COVID-19 vaccine, it would quickly get the job done toward finalization and issuance of an emergency use authorization for the COVID-19 vaccine. 

The Fda gave no specific timeline.

The agency has also notified the U.S. Facilities for Disease Command and Avoidance and Operation Warp Pace, so they can execute their options for timely vaccine distribution.

Approval implies vaccine distribution would be on Operation Warp Speed’s plan for distribution to entrance-line healthcare workers and susceptible populations in extended-expression treatment amenities by mid-thirty day period.

The Fda advisory committee has scheduled a different conference to assessment the Moderna vaccine on Thursday, December 17.

See our continuing vaccine protection listed here:

Pfizer-BioNTech vaccine gets Fda advisory committee acceptance

CMS provides assistance in billing Medicare for COVID-19 antibody therapy

Hundreds in the United Kingdom are the to start with to obtain Pfizer COVID-19 vaccine

Eli Lilly and UnitedHealth Team husband or wife on COVID-19 antibody therapy for significant-hazard people

Operation Warp Pace is hunting to get started distributing COVID-19 vaccine by mid-thirty day period

Moderna seeks regulatory authorization for its COVID-19 vaccine

HHS will begin allocating Regeneron’s COVID-19 therapeutic this week

HHS associates with chain and impartial pharmacies to enhance obtain to potential COVID-19 vaccines

COVID-19 vaccine distribution will begin in 24 hours of an emergency use authorization

Moderna vaccine candidate reveals 94.5% efficacy against COVID-19

Pfizer touts new COVID-19 vaccine, contacting it ‘90% effective’

Medicare beneficiaries can get monoclonal antibody COVID-19 treatment options at no price tag

Fda grants emergency use authorization for Eli Lilly antibody therapy for COVID-19

Twitter: @SusanJMorse
E-mail the author: [email protected]